Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)

Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93; Golfieri, R. (Rita)|||/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5; Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f; Pfammatter, T. (Thomas)|||/items/c83b27c3-39b1-4a15-825e-c36159a6fedf; Arnold, D. (Dirk)|||/items/099bd9e3-21b5-4667-b221-019be2f28370; Cianni, R. (Roberto)|||/items/44136911-1445-4958-bb06-51b0c81a263a; Maleux, G. (Geert)|||/items/f9cabf53-a062-4f9b-8099-301cdb26555e; Munneke, G. (Graham)|||/items/33afac81-9bd0-4391-b00c-2ab2a29e2103; Pellerin, O. (Olivier)|||/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e; Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16; Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49; Schaefer, N. (Niklaus)|||/items/e3405054-aec1-45e4-8aed-64763da49bc9; Jong, N. (Niels) de|||/items/c5c5d9da-4d8e-45f7-814b-52a5924df343; Bilbao, J.I. (José I.)|||/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88

Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)

Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Ther...

Descripción completa

Detalles Bibliográficos
Autores:	Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93, Golfieri, R. (Rita)\|\|\|/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5, Pech, M. (Maciej)\|\|\|/items/3952e467-7f56-4131-afac-c7864104471f, Pfammatter, T. (Thomas)\|\|\|/items/c83b27c3-39b1-4a15-825e-c36159a6fedf, Arnold, D. (Dirk)\|\|\|/items/099bd9e3-21b5-4667-b221-019be2f28370, Cianni, R. (Roberto)\|\|\|/items/44136911-1445-4958-bb06-51b0c81a263a, Maleux, G. (Geert)\|\|\|/items/f9cabf53-a062-4f9b-8099-301cdb26555e, Munneke, G. (Graham)\|\|\|/items/33afac81-9bd0-4391-b00c-2ab2a29e2103, Pellerin, O. (Olivier)\|\|\|/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e, Peynircioglu, B. (Bora)\|\|\|/items/fca68796-d81a-436f-b61d-f6738027cc16, Sangro-Gómez-Acebo, B.C. (Bruno Carlos)\|\|\|/items/594bbdbb-046a-4ab2-878c-cb4fe577af49, Schaefer, N. (Niklaus)\|\|\|/items/e3405054-aec1-45e4-8aed-64763da49bc9, Jong, N. (Niels) de\|\|\|/items/c5c5d9da-4d8e-45f7-814b-52a5924df343, Bilbao, J.I. (José I.)\|\|\|/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88
Tipo de recurso:	artículo
Fecha de publicación:	2021
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/115041
Acceso en línea:	https://hdl.handle.net/10171/115041
Access Level:	acceso abierto
Palabra clave:	Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90

id	ES_6d0bb3a1e2da2ae2be2768f541ff6a2b
oai_identifier_str	oai:dadun.unav.edu:10171/115041
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93Golfieri, R. (Rita)\|\|\|/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5Pech, M. (Maciej)\|\|\|/items/3952e467-7f56-4131-afac-c7864104471fPfammatter, T. (Thomas)\|\|\|/items/c83b27c3-39b1-4a15-825e-c36159a6fedfArnold, D. (Dirk)\|\|\|/items/099bd9e3-21b5-4667-b221-019be2f28370Cianni, R. (Roberto)\|\|\|/items/44136911-1445-4958-bb06-51b0c81a263aMaleux, G. (Geert)\|\|\|/items/f9cabf53-a062-4f9b-8099-301cdb26555eMunneke, G. (Graham)\|\|\|/items/33afac81-9bd0-4391-b00c-2ab2a29e2103Pellerin, O. (Olivier)\|\|\|/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316ePeynircioglu, B. (Bora)\|\|\|/items/fca68796-d81a-436f-b61d-f6738027cc16Sangro-Gómez-Acebo, B.C. (Bruno Carlos)\|\|\|/items/594bbdbb-046a-4ab2-878c-cb4fe577af49Schaefer, N. (Niklaus)\|\|\|/items/e3405054-aec1-45e4-8aed-64763da49bc9Jong, N. (Niels) de\|\|\|/items/c5c5d9da-4d8e-45f7-814b-52a5924df343Bilbao, J.I. (José I.)\|\|\|/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88Hepatocellular carcinomaLiverMetastasisObservational studyRadioisotope brachytherapyRegistriesTherapeutic embolizationTrans-arterial radioembolizationYttrium-90Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and methods: Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results: Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion: In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence: Level 3. Trial registration: ClinicalTrials.gov NCT02305459.Springer NatureDadun. Depósito Académico Digital Universidad de Navarra20212021-01-0120212021-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/115041reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1150412026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
title	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
spellingShingle	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90
title_short	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
title_full	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
title_fullStr	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
title_full_unstemmed	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
title_sort	Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
dc.creator.none.fl_str_mv	Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Golfieri, R. (Rita)\|\|\|/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)\|\|\|/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)\|\|\|/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)\|\|\|/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)\|\|\|/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)\|\|\|/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)\|\|\|/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)\|\|\|/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)\|\|\|/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)\|\|\|/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)\|\|\|/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de\|\|\|/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)\|\|\|/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88
author	Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93
author_facet	Helmberger, T. (Thomas)\|\|\|/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Golfieri, R. (Rita)\|\|\|/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)\|\|\|/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)\|\|\|/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)\|\|\|/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)\|\|\|/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)\|\|\|/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)\|\|\|/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)\|\|\|/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)\|\|\|/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)\|\|\|/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)\|\|\|/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de\|\|\|/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)\|\|\|/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88
author_role	author
author2	Golfieri, R. (Rita)\|\|\|/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)\|\|\|/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)\|\|\|/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)\|\|\|/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)\|\|\|/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)\|\|\|/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)\|\|\|/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)\|\|\|/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)\|\|\|/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)\|\|\|/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)\|\|\|/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de\|\|\|/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)\|\|\|/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88
author2_role	author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90
topic	Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90
description	Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and methods: Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results: Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion: In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence: Level 3. Trial registration: ClinicalTrials.gov NCT02305459.
publishDate	2021
dc.date.none.fl_str_mv	2021 2021-01-01 2021 2021-01-01
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/115041
url	https://hdl.handle.net/10171/115041
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Springer Nature
publisher.none.fl_str_mv	Springer Nature
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869410311811891200
score	15.811543

Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)

Similares en LA Referencia